Demographic data, clinical findings, and treatment status in the study population.
| Characteristic | 1-SS, n = 56 | 2-SS, n = 24 |
|---|---|---|
| Median age (range), yrs | 59 (24–80) | 64 (33–73) |
| Female, % | 100 | 100 |
| Median disease duration (range), yrs | 3 (0–29) | 6 (0–30) |
| Sicca symptoms, oral only/ocular only/both, n | 5/10/30 | 4/3/10 |
| Patients with respiratory symptoms, n (%) | 11 (20) | 8 (33) |
| Patients with anti-SSA/Ro, n (%) | 46 (82) | 14 (58) |
| Patients with anti-SSB/La, n (%) | 17 (30) | 4 (16) |
| Patients with leukopenia < 3500 mm3, n (%) | 24 (43) | 9(38) |
| Serum IgG, mg/dl, mean ± SD | 2337 ± 1109 | 2153 ± 754 |
| Patients with extraglandular manifestations, n (%) | 29 | — |
| Patients with cLPD, n (%) | 11 | 0 |
| Associated connective tissue diseases | — | SSc 9, RA 5, SLE 5, PM 2, |
| MCTD l, OS 2 | ||
| Corticosteroid dose, mg/day, mean (range) | 2.0 (0–20) | 5.8 (0–40) |
| Patients without corticosteroid therapy, n (%) | 37 (66) | 11 (46) |
| Patients on corticosteroid therapy, n | 19 | 13 |
| > 0 and ≤ 5 mg/day | 14 | 4 |
| > 5 and ≤ 10 mg/day | 4 | 6 |
| > 10 and ≤20 mg/day | 1 | 2 |
| > 20 mg/day | 0 | 1 |
| Patients on immunosuppressants*, n | 3 | 4 |
↵* All patients were receiving corticosteroid therapy. cLPD: clonally derived lymphoproliferative disorder; SSc: systemic sclerosis; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; PM: polymyositis; MCTD: mixed connective tissue disease; OS: overlap syndrome.